Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of isotretinoin when given
together with vorinostat and to see how well they work in treating patients with advanced
kidney cancer. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Isotretinoin may cause kidney cancer cells to look more like normal
cells, and to grow and spread more slowly. Giving vorinostat together with isotretinoin may
kill more tumor cells.